International Federation of Pharmaceutical Manufacturers and Associations
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [1] It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [2]
History
Positions
Individuals
IFPMA President
- Dr. Daniel Vasella, Chairman and Chief Executive Officer Novartis International AG
IFPMA Vice Presidents
- Dr. Henry A. McKinnell, Jr., Chairman and Chief Executive Officer Pfizer Inc.
- Haruo Naito, President and Chief Executive Officer Eisai Co. Ltd.
Directors
- Dr. Harvey E. Bale, Jr., Director General
- Dr. Odette Morin, Director, Regulatory and Scientific Affairs
- Dr. Eric Noehrenberg, Director, International Trade and Market Policy
- Dr. Ryoko Krause, Director, Biologicals and Vaccines
- Dr. Frédérique Santerre, Health Care Systems (ad-interim)
- Mr. Guy Willis, Director of Communications
- Mr. Takeshi Sano, Japan Liaison Executive
Members
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:
- Abbott Laboratories
- Akzo Nobel – Organon
- Almirall-Prodesfarma
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Eisai
- Eli Lilly
- Esteve
- F-Hoffmann-La Roche
- Astellas Pharma Inc.
- GlaxoSmithKline
- Merck & Co., Inc.
- Menarini S.A.
- Merck KGaA
- Novartis International AG
- Pfizer
- Sanofi-Aventis
- Institut de Recherches Internationales Servier – I.R.I.S.
- Sigma-Tau
- Schering AG
- Schering-Plough
- Takeda
- Wyeth